Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials

Clinical Research in Cardiology

Volumn 108, Issue 5, 2019, Pages 477-486

  Rossello, Xavier ^a,b,c   Ariti, Cono ^b,d   Pocock, Stuart J ^a,b   Ferreira, João Pedro ^e   Girerd, Nicolas ^e   McMurray, John J V ^f   Van Veldhuisen, Dirk J ^g   Pitt, Bertram ^h   Zannad, Faiez ^e  

^a CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c CIBER de enfermedades CardioVasculares ^*  (Spain)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e UNIVERSITÉ DE LORRAINE   (France)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^h UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Heart failure; Left ventricular dysfunction; Meta analysis; Mineralocorticoid receptor antagonists; Randomized clinical trials; Sudden cardiac death

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; EPLERENONE; MINERALOCORTICOID ANTAGONIST; POTASSIUM; SPIRONOLACTONE;

AGE; ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL OUTCOME; DEATH; DEFIBRILLATION; FOLLOW UP; HEART ARRHYTHMIA; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; HYPERKALEMIA; KIDNEY DISEASE; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); THERAPY EFFECT; COMPLICATION; HEART LEFT VENTRICLE FUNCTION; PATHOPHYSIOLOGY; PROCEDURES; RISK FACTOR; SUDDEN CARDIAC DEATH; SYSTOLE;

DEATH, SUDDEN, CARDIAC; HEART FAILURE; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SPIRONOLACTONE; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 85053936460     PISSN: 18610684     EISSN: 18610692     Source Type: Journal    
DOI: 10.1007/s00392-018-1378-0     Document Type: Article

References (37)

1. MERIT-HF-Investigators (1999) Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet 353:2001–2007
2. Domanski MJ, Exner DV, Borkowf CB et al (1999) Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction. A meta-analysis of randomized clinical trials. J Am Coll Cardiol 33:598–604
3. Desai AS, McMurray JJV, Packer M et al (2015) Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 36:1990–1997. 10.1093/eurheartj/ehv186
4. Shen L, Jhund PS, Petrie MC et al (2017) Declining risk of sudden death in heart failure. N Engl J Med 377:41–51. 10.1056/NEJMoa1609758
5. Køber L, Thune JJ, Nielsen JC et al (2016) Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 375:1221–1230. 10.1056/NEJMoa1608029
6. Ponikowski P, Voors AA, Anker SD et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37:2129–2200. 10.1093/eurheartj/ehw128
7. Yancy CW, Jessup M, Bozkurt B et al (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62:e147–e239. 10.1016/j.jacc.2013.05.019
8. Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709–717. 10.1056/NEJM199909023411001
9. Zannad F, McMurray JJV, Krum H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11–21. 10.1056/NEJMoa1009492
10. Pitt B, Remme W, Zannad F et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–1321. 10.1056/NEJMoa030207
11. Bossard M, Binbraik Y, Beygui F et al (2018) Mineralocorticoid receptor antagonists in patients with acute myocardial infarction—a systematic review and meta-analysis of randomized trials. Am Heart J 195:60–69. 10.1016/j.ahj.2017.09.010
12. Guglin M, Awad KE, Polavaram L, Vankayala H (2007) Aldosterone antagonists: the most underutilized class of heart failure medications. Am J Cardiovasc Drugs 7:75–79
13. Bistola V, Simitsis P, Farmakis D et al (2018) Association of mineralocorticoid receptor antagonist use and in-hospital outcomes in patients with acute heart failure. Clin Res Cardiol 107:76–86. 10.1007/s00392-017-1161-7
14. Perrier E, Kerfant B-G, Lalevee N et al (2004) Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction. Circulation 110:776–783. 10.1161/01.CIR.0000138973.55605.38
15. Pitt B (1995) “Escape” of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc drugs Ther 9:145–149
16. Ouvrard-Pascaud A, Sainte-Marie Y, Bénitah J-P et al (2005) Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 111:3025–3033. 10.1161/CIRCULATIONAHA.104.503706
17. Bapoje SR, Bahia A, Hokanson JE et al (2013) Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials. Circ Heart Fail 6:166–173. 10.1161/CIRCHEARTFAILURE.112.000003
18. da Costa BR, Jüni P (2014) Systematic reviews and meta-analyses of randomized trials: principles and pitfalls. Eur Heart J 41:3336–3345. 10.1093/eurheartj/ehu424
19. Riley RD, Lambert PC, Abo-Zaid G (2010) Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 340:c221
20. Rossignol P, Girerd N, Bakris G et al (2017) Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia. Eur J Heart Fail 19:792–799. 10.1002/ejhf.688
21. Solomon SD, Zelenkofske S, McMurray JJV et al (2005) Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med 352:2581–2588. 10.1056/NEJMoa043938
22. Le H-H, El-Khatib C, Mombled M et al (2016) Impact of aldosterone antagonists on sudden cardiac death prevention in heart failure and post-myocardial infarction patients: a systematic review and meta-analysis of randomized controlled trials. PLoS One 11:e0145958. 10.1371/journal.pone.0145958
23. Bardy GH, Lee KL, Mark DB et al (2005) Amiodarone or an implantable cardioverter–defibrillator for congestive heart failure. N Engl J Med 352:225–237. 10.1056/NEJMoa043399
24. McMurray JJV, Krum H, Abraham WT et al (2016) Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med 374:1521–1532. 10.1056/NEJMoa1514859
25. Miller AL, Wang Y, Curtis J et al (2012) Optimal medical therapy use among patients receiving implantable cardioverter/defibrillators: insights from the National Cardiovascular Data Registry. Arch Intern Med 172:64–67. 10.1001/archinternmed.2011.466
26. Fonarow GC, Yancy CW, Hernandez AF et al (2011) Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. Am Heart J 161:1024–1030. 10.1016/j.ahj.2011.01.027
27. Sanders GD, Hlatky MA, Owens DK (2005) Cost-effectiveness of implantable cardioverter–defibrillators. N Engl J Med 353:1471–1480. 10.1056/NEJMsa051989
28. Moss AJ, Zareba W, Hall WJ et al (2002) Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346:877–883. 10.1056/NEJMoa013474
29. Stanek EJ, Oates MB, McGhan WF et al (2000) Preferences for treatment outcomes in patients with heart failure: symptoms versus survival. J Card Fail 6:225–232. 10.1054/jcaf.2000.9503
30. Stambler BS, Laurita KR, Shroff SC et al (2009) Aldosterone blockade attenuates development of an electrophysiological substrate associated with ventricular tachyarrhythmias in heart failure. Heart Rhythm 6:776–783. 10.1016/j.hrthm.2009.02.005
31. Ferreira JP, Girerd N, Medeiros PB et al (2016) Spot urine sodium excretion as prognostic marker in acutely decompensated heart failure: the spironolactone effect. Clin Res Cardiol 105:489–507. 10.1007/s00392-015-0945-x
32. Cooper HA, Dries DL, Davis CE et al (1999) Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 100:1311–1315
33. Aldahl M, Jensen A-SC, Davidsen L et al (2017) Associations of serum potassium levels with mortality in chronic heart failure patients. Eur Heart J 38:2890–2896. 10.1093/eurheartj/ehx460
34. Vukadinović D, Lavall D, Vukadinović AN et al (2017) True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: a meta-analysis. Am Heart J 188:99–108. 10.1016/j.ahj.2017.03.011
35. Wei L, Struthers AD, Fahey T et al (2010) Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ 340:c1768–c1768. 10.1136/bmj.c1768
36. Weir MR, Bakris GL, Bushinsky DA et al (2015) Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 372:211–221. 10.1056/NEJMoa1410853
37. Iqbal J, Parviz Y, Pitt B et al (2014) Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure. Eur J Heart Fail 16:143–150. 10.1111/ejhf.31